Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Completed · Phase 2 · Has a placebo group
Conditions studied: Covid19
In brief
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
Key facts
- Study ID
- NCT04551898
- Run by
- BeiGene
- People needed
- 181
- Starts
- 2020-12-02
- Expected to finish
- 2021-05-25
- Last updated by the study team
- 2024-10-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Btc Network Midland Florida Clinical Research Center — DeLand, Florida, United States
- Elixia Clinical Research Collaborative — Hollywood, Florida, United States
- Homestead Associates in Research Inc — Miami, Florida, United States
- Medical Research Center of Miami Ii, Inc — Miami, Florida, United States
- Us Associates in Research — Miami, Florida, United States
- Continental Research Network — Miami, Florida, United States
- Orlando Health Ufhealth Cancer Center — Orlando, Florida, United States
- Revive Research Institute — Dearborn, Michigan, United States
- Revival Research Institute Farmington Hills — Sterling Heights, Michigan, United States
- Amarillo Center For Clinical Research — Amarillo, Texas, United States
- Panamerican Clinical Research Us Headquarters — Brownsville, Texas, United States
- Hospital Das Clinicas Da Faculdade de Medicina de Botucatu — Botucatu, Brazil
- Fundacao Universidade de Caxias Do Sul — Caxias do Sul, Brazil
- Consultoria Medica E Pesquisa Clinica — Sorcaba, Brazil
- Hospital Cardiologica Aguascalientes — Aguascalientes, Mexico
- IECSI — Monterrey, Mexico
- Task Clinical Research Centre — Cape Town, South Africa
- Langeberg Clinical Trials — Cape Town, South Africa
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.